Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR

Phase 3 Not yet recruiting 120 enrolled Meshalkin Research Institute of Pathology of Circulation

RandomizedParallel-groupOpen-labelTreatment

Summary

SAFE-HEART is a single-centre, randomized controlled trial comparing the safety and efficiency of Apixaban versus Warfarin in the early period (3 months) after repair or bioprosthetics of the mitral and aortic valve cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.

Timeline

Start: 2026-02
Primary completion: 2028-01
Completion: 2029-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Apixaban	Small molecule	—	Oral
Comparator	Warfarin	Small molecule	—	Oral

Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR

Summary

Timeline

Drugs

Indications